Grant of Share Options to Chief Executive Officer

AI SummaryClose X

Shield Therapeutics PLC announced on October 13, 2025, the grant of share options to its Group CEO, Anders Lundstrom, under the company's Retention and Performance Share Plan (RPSP) as part of his 2025 annual equity grant. Lundstrom, a person discharging managerial responsibility, received options over 1,547,262 ordinary shares. These options vest in three equal tranches over three years from the grant date, contingent on his continued employment. The option awards represent approximately 0.1% of the total number of AIM securities currently in issue. The exercise price for these options is 1.5 pence per share. Lundstrom currently holds 585,000 ordinary shares in the company.

Disclaimer*

UK 100

Latest directors dealings